NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Clarivate Q1 revenue edges past estimates, earnings in line

EditorRachael Rajan
Published 08/05/2024, 11:44
© Reuters.
CLVT
-

LONDON - Clarivate Plc (NYSE: CLVT), a global leader in providing trusted insights and analytics, reported first-quarter earnings that met analyst expectations and revenue that slightly exceeded forecasts.

For the quarter ended March 31, 2024, the company posted adjusted earnings per share (EPS) of $0.14, aligning with the consensus estimate. Revenue reached $621.2 million, surpassing the analyst consensus of $614.85 million and marking a slight decline of 1.3% from the previous year's $629.1 million.

The company's organic revenue saw a decrease of 1.7%, primarily due to a drop in transactional and other revenues of 11.4% and re-occurring revenues of 5.1%. This decline was partially offset by a 2.4% increase in subscription revenues. The net loss attributable to ordinary shares stood at $93.8 million, a significant shift from the net income of $24.7 million reported in the same quarter last year.

Jonathan Gear, Chief Executive Officer of Clarivate, highlighted the company's progress in key objectives, including product investments and operational initiatives aimed at driving future organic revenue growth.

"Our Intellectual Property segment refined its go-to-market operating model and revived patent intelligence solutions, resulting in commercial success across our software solutions, particularly IPFolio, and improved Derwent renewal rates," said Gear.

For the full year 2024, Clarivate reaffirmed its outlook, anticipating adjusted EPS in the range of $0.70 to $0.80, with the midpoint of $0.75 falling slightly above the consensus estimate of $0.74. The company expects revenue to be between $2.57 billion and $2.67 billion, with the midpoint of $2.62 billion matching the analyst consensus.

The company's financial performance reflects ongoing investments in product development and strategic acquisitions, such as MotionHall and Global QMS, Inc., aimed at enhancing its portfolio in the Life Sciences & Healthcare segment. Despite a decrease in free cash flow, which fell by $56.4 million to $111.8 million, and a decrease in net cash provided by operating activities, which dropped by $51.3 million to $176.2 million, Clarivate remains committed to revitalizing its operations and delivering value to clients, colleagues, and shareholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.